Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2646264 in Cutaneous Lupus Erythematosus
NCT02927457Phase 1Completed
- Sponsor
- GSK
- Start
- Jan 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK2646264 in cutaneous lupus erythematosus (CLE) (6 arms), sponsored by GSK. Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs), Number of Participants With Emergent Chemistry Results by Potential Clinical Importance (PCI) Criteria at Day 56 and 3 more. Started Jan 2017; status: completed.
02
Drugs
GSK2646264
03
Conditions
cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT02927457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02927457.